SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Valentis (VLTS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (54)6/15/2001 6:55:44 PM
From: Mike McFarland  Read Replies (1) of 81
 
Yes, this apparently started at Megabios...
Valentis also has an exclusive license from Vanderbilt
covering Vanderbilt’s interest in the del-1 gene and
protein. Valentis acquired the Second Vanderbilt License
by assignment from Progenitor, Inc. as part of the purchase
of the del-1 rights held by Progenitor in April 1999.
--off the Valentis website

Thanks for the way over to the inactive PGEN thread.

Sector liquidity? I don't see a lot of that reflected
in my companies...and with only a year of cash left at
Valentis, I sure hope that PolyMasc has some value.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News